ONCOLOGIST 润色咨询

ONCOLOGIST

出版年份:1996 年文章数:3179 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:3.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2020-07-30 doctor0805

    审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0
    偏重的研究方向:临床
    经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。
    另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!

    13

    展开13条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2023-05-04 doctor0805 来自北京

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。
    这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。
    不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!

    8

    展开8条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-04-07 1260965917

    审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0
    偏重的研究方向:乳腺癌;临床研究;个案+综述
    经验分享:2020.6.18投稿,with editor
    2020.7.21 decision in process
    2020.9.10催稿 under review
    中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理
    2021.1.5收到大修的邮件
    2021.2.10文章修回
    2021.3.8第一次催稿未理会
    2021.4.6第二次催稿求理会......

    6

    展开6条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-07-04 DyralDeng

    一个月了,还是under review

    6

    展开6条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2019-01-02 123b9b72m07暂无昵称

    请问有没有under review半年的,发邮件也不回复

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2019-03-16 1e1db0a2m84(暂无匿称)

    有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2019-03-09 Kobe Byrant

    一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊sunliang 2019-03-02 发表::
    听说这个杂志也是水刊?大家有什么看法?
    sunliang 2019-03-02 00:00:00 发表:
    听说这个杂志也是水刊?大家有什么看法?

    sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2023-06-17 watng

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:普外科
    经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2019-12-17 ruicosta111

    返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=805176, encodeId=04c98051e6a9, content=审稿速度:3.0 | 投稿命中率:50.0 | 审稿费用:90.0 | 版面费用:1500.0<br>偏重的研究方向:临床<br>经验分享:第一次投稿,写了文章后先是吹牛投了JCO,被拒后偷偷注册了老板的邮箱,开始四处投稿,投的都是自己知道的,比如BMC cancer, breast cancer等,都被拒了。BMC被拒有点伤心,因为那个是3分左右的文章,后面就不知道怎么办了,也不想投了(每次投完都没改过),然后就看到这个杂志,本着随便投投,免得被老板问怎么样的心态,3月份投稿,结果4月份返修,major revision,特别激动!那时候还搜了搜major 被拒的可能性,网友说还是会被拒的,迅速改完后,4月31返回,一周后minor revision,认真改了后一周内返回。结果就是6月份录用,真是激动。<br>另外要说的就是审稿费,因为当时奔着随便投的去的,而且也没指望录用,当时投JCO的时候也交了,然后就被拒了,更何况这个也不报销,当时让我缴费的时候,正好英文老师教我们如何写cover letter,其中一个章节就是如何和杂志说你很穷,来自发展中国家等,于是我就把那个抄过去了,说我是个学生,来自发展中的国家,经费有限,还不给报销之类的,结果就是真没要我的版面费,哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu Jul 30 11:47:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2130125, encodeId=60722130125f0, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:oncologist其实不好中,我有两次投稿经历,一次是17年,心得已经发在前面了,另一次是这个。去年11月份,隔离在酒店,师妹的文章发给我,让我改,看着内容写得并不好,随便改改,领导看了后,为了鼓励我用心改,同意让我共通,所以才下功夫改了。花了1一个月时间,到1月初的时候投稿,选了个oncologist,想着试一试。结果第二天就under review了。审了两个月,领导等不及,一直再问,让发个邮件问一问,写了个邮件,发的第二天,人家就给minor review了,一个审稿人提了大概7-8个问题,有的好回答,有的不太好回答,就仔细回答了,给了三周时间,前两周师妹在改,我就没过问,最后一周还是拿来自己改了改,周三是返稿的deadline, 周二返稿,周四accept。<br>这次投稿真的很顺,under review很快,给的返修以来就是minor,然后accept只要两天,也没有语言问题。我都怀疑这篇文章是不是应该投高点了。<br>不过结果挺好的,2周后又中了一篇3.7分的文章,看着挺好的,但是这几篇都不够我出站的,出站必须要唯一一作,且Q2,满足这个有点难,好在3.7分文章接收的同时,另一篇13分的文章也返修了,没说是major 还是minor,只说了we are interested in your paper but not in its current state,希望好运,求好运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Thu May 04 22:16:11 CST 2023, time=2023-05-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=954413, encodeId=81a79544134e, content=审稿速度:6.0 | 投稿命中率:25.0 | 审稿费用:90.0 | 版面费用:2500.0<br>偏重的研究方向:乳腺癌;临床研究;个案+综述<br>经验分享:2020.6.18投稿,with editor<br>2020.7.21 decision in process<br>2020.9.10催稿 under review<br>中间2次催稿,均受到编辑回信,under review状态前的时间不断更新,提示编辑确实在处理<br>2021.1.5收到大修的邮件<br>2021.2.10文章修回<br>2021.3.8第一次催稿未理会<br>2021.4.6第二次催稿求理会......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23be4781508, createdName=1260965917, createdTime=Wed Apr 07 09:46:15 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996152, encodeId=92d599615209, content=一个月了,还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:47:04 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565067, encodeId=7c7b56506ec0, content=请问有没有under review半年的,发邮件也不回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6d72431749, createdName=123b9b72m07暂无昵称, createdTime=Wed Jan 02 00:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568176, encodeId=0f175681e65e, content=有没有投稿 5个月,发邮件 不回,要去撤稿,也不理会的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/7f2f58e7cd39af3548e526ce03d288e5/35d99bd608116038c280e861823db7ef.jpg, createdBy=cc822005876, createdName=1e1db0a2m84(暂无匿称), createdTime=Sat Mar 16 10:04:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567854, encodeId=0e7b56e854e7, content=一半的article都是II和III期临床试验,一篇修回的文章刚刚被拒,难度很大;另外一篇刚刚修回;你可以尝试中一篇,在谈是不是水刊<span class="quote">sunliang 2019-03-02 发表::<br>听说这个杂志也是水刊?大家有什么看法?</span><span class="quote">sunliang 2019-03-02 00:00:00 发表:<br>听说这个杂志也是水刊?大家有什么看法?</span>, beContent=sunliang 2019-03-02 发表:: 听说这个杂志也是水刊?大家有什么看法?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/23/cd7766c7f7b6194d91ad94686c8a4352.jpg, createdBy=daad1978009, createdName=Kobe Byrant, createdTime=Sat Mar 09 00:00:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143305, encodeId=e573214330582, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:普外科<br>经验分享:一多月审稿结束,修回。审稿人的建议我们没有完全实现,解释了理由,审稿人应该是理解并同意了。第二次修回时,只有编辑提了一些小问题,一个星期内accept。总体感觉很严谨,也相对友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo1XZ4oEVSFHIYMCMWm1wRpVTQ4y1ePTLmA5aS4KlfkY4oj0icfWpJz7sDDiakzyD2ibNw/132, createdBy=98a62105116, createdName=watng, createdTime=Sat Jun 17 11:03:57 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581660, encodeId=caab581660d1, content=返修过去3个月,没有任何消息,写信也不回,不清楚是怎么回事!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/yk3Ok9Palo9XeaUCxlW1rGtX62ibXjvyib7amSbLbQNXFYEC7XcYx4BZicEv2VlIjph17ThxMgBgIGLyaEQNceRYQ/132, createdBy=a7942020383, createdName=ruicosta111, createdTime=Tue Dec 17 00:00:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006272, encodeId=43e110062e291, content=请问这期刊接受 case report 吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4e1869736, createdName=ms4250921918312946, createdTime=Mon Aug 09 10:49:18 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 ms4250921918312946

    请问这期刊接受 case report 吗?

    3

    展开3条回复
共116条页码: 1/12页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分